BMJ7d
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...
BMJ9d
2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease by Wallace et al
Correspondence to Professor Sang-Won Lee, Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea (the Republic of); SANGWONLEE{at}yuhs.ac The mean age of the patients was 60.2 ...
BMJ4d
Methotrexate: what are the true risks of treatment?
For more than three decades, low-dose methotrexate (MTX) has been the first-line treatment for patients with rheumatoid arthritis (RA). Even after the introduction of biologics/biosimilars and janus ...
BMJ3d
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis
Correspondence to Dr Chuan-ju Liu, Rm 1608, HJD, Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York NY10003, USA; chuanju.liu{at}nyumc.org Objective ...
BMJ10d
Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI
Correspondence to HW van Steenbergen, Department of Rheumatology, Leiden University Medical Center, P O Box 9600, Leiden 2300 RC, The Netherlands; h.w.van_steenbergen{at}lumc.nl Background The phase ...
BMJ4d
XBP1: the last two decades
Correspondence to Dr L H Glimcher, Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, FXB 205, Boston, MA 02115, USA; ...
BMJ11d
OP0211 CHANGE IN URINARY BIOMARKERS AT THREE MONTHS PREDICTS 1-YEAR TREATMENT RESPONSE OF LUPUS NEPHRITIS BETTER THAN PROTEINURIA
1 Johns Hopkins University, Rheumatology, Baltimore, United States of America 2 NYU Grossman School of Medicine, Division of Rheumatology, New York, United States of America 3 University of Maryland, ...
BMJ12d
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis
Objective To compare the effects of interleukin-6 (IL-6) receptor and tumour necrosis factor inhibition on inducing repair of existing bone erosions in patients with very early rheumatoid arthritis ...
BMJ6d
AB0564 THE CONTROVERSIAL ROWELL SYNDROME: TO BE OR NOT TO BE?
Background: Rowell syndrome is a rather rare and highly debated entity, initially defined by Rowell et all as discoid lupus associated with erythema multiforme-like (EM) lesions, positive speckled ANA ...
BMJ10d
Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
Correspondence to Dr. Kornelis S M van der Geest, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9712 CP Groningen, Netherlands; ...
BMJ13d
Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative
Objectives Osteoarthritis (OA) structural status is imperfectly classified using radiographic assessment. Statistical shape modelling (SSM), a form of machine-learning, provides precise quantification ...
BMJ9d
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual
Background The European Scleroderma Trials and Research Group (EUSTAR) recently developed a preliminarily revised activity index (AI) that performed better than the European Scleroderma Study Group ...